Format

Send to

Choose Destination
Am J Health Behav. 2017 Jan;41(1):16-32.

E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies.

Author information

1
Principal Scientist and Head of Clinical Research, British American Tobacco (Investments) Limited, Research and Development, Southampton, United Kingdom (UK).
2
Scientist II Clinical Research, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK.
3
Senior Scientist Clinical Research, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK.
4
Senior Statistician, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK.
5
President, Los Angeles Clinical Trials, Burbank, CA.
6
Head of NGP Safety Assessment, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK.
7
Chief Scientific Officer, British American Tobacco (Investments) Limited, Research and Development, Southampton, UK;, Email: ian_fearon@bat.com.

Abstract

OBJECTIVES:

E-cigarettes could potentially play a major role in tobacco harm reduction by delivering nicotine in a vapor containing significantly fewer toxicants than cigarette smoke and may aid smoking behavior changes such as reduction or cessation.

METHODS:

We examined blood nicotine levels in smokers who were non-accustomed to e-cigarette use (Study 1) and accustomed e-cigarette users (Study 2). We compared nicotine levels when participants used a closed modular system e-cigarette to those when participants smoked a cigarette.

RESULTS:

In Study 1, Cmax (geometric mean (CV)) during a 5-minute puffing period (10 puffs, 30 seconds apart) was 13.4 (51.4) ng/ ml for a regular cigarette. The e-cigarette Cmax was significantly lower (p .05) at 2.5 (67.8) ng/ml. In Study 2, during a 5-minute ad libitum puffing period, cigarette Cmax was 7.2 (130.8) ng/mL, and it was 7.8 (108.2) ng/mL for the e-cigarette.

CONCLUSIONS:

Our data demonstrate heterogeneity of nicotine deliveries both between products and also with the same products used by different cohorts, eg, accustomed users versus smokers. Such differences must be taken into account when determining the likely behavioral impact, on smoking reduction and cessation, of nicotine delivery data and when planning e-cigarette nicotine pharmacokinetic studies.

PMID:
27935787
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center